2. Search Result
Search Result
Results for "

gastric mucus

" in MedChemExpress (MCE) Product Catalog:

10

Inhibitors & Agonists

1

Natural
Products

2

Antibodies

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-B0758
    Troxipide

    		Calcium Channel Inflammation/Immunology
    Troxipide is an orally active defensive factor-enhancing therapeutic agent for gastritis and gastric ulcer (GU). Troxipide is a non-antisecretory gastro protective agent with antiulcer, anti-inflammatory and mucus-secreting properties .
    Troxipide
  • HY-100958
    4-DAMP
    4 Publications Verification

    4-DAMP methiodide

    		 mAChR Apoptosis MMP EGFR Interleukin Related Inflammation/Immunology Cancer
    4-DAMP (4-DAMP methiodide) is a potent and selective antagonist of M3 receptors and also has a high affinity for the closely-related M5 receptors. 4-DAMP combined with 5-Fluorouracil (5-Fu) (HY-90006) could significantly reduce the cell viability and enhance apoptosis in MKN45 and BGC823 gastric cancer cells. 4-DAMP inhibits lipopolysaccharide (LPS)- and tobacco-induced pulmonary inflammation and reduces mucin 5AC (MUC5AC), oligomeric mucus/gel-forming secretion .
    4-DAMP
  • HY-B0160
    Lafutidine

    FRG-8813

    		 Histamine Receptor Metabolic Disease Endocrinology
    Lafutidine (FRG-8813) is a histamine H2-receptor antagonist (H2RA), with proven gastric mucosal protective effects. Lafutidine can be used for the research of gastroesophageal reflux disease .
    Lafutidine
  • HY-N1510
    Kaempferol 3-O-gentiobioside

    		Glycosidase Notch Toll-like Receptor (TLR) NF-κB Mucin Reactive Oxygen Species (ROS) Bacterial TGF-beta/Smad Anaplastic lymphoma kinase (ALK) Infection Inflammation/Immunology Cancer
    Kaempferol 3-O-gentiobioside is an orally active flavonoid, with a Ka value of 57 µM against human NOTCH1 and an IC50 value of 50 μM against α-glucosidase. Kaempferol 3-O-gentiobioside inhibits the NOTCH signaling pathway. It downregulates the expression of TLR4 and NLRP3, and suppresses the activation and nuclear translocation of NF-κB. Kaempferol 3-O-gentiobioside inhibits the expression of MUC5AC, reduces nitrite and ROS levels, and attenuates excessive mucus secretion. It exhibits antibacterial activity, reducing the formation and growth of MRSA biofilms. Kaempferol 3-O-gentiobioside blocks the TGF-β/ALK5/Smad signaling pathway and inhibits epithelial-mesenchymal transition. It suppresses the proliferation, migration, invasion and metastatic growth of tumor cells. Kaempferol 3-O-gentiobioside alleviates airway inflammation and mucus hypersecretion in mice with allergic asthma . It reduces the volume of ovarian cancer xenografts in mice. Kaempferol 3-O-gentiobioside can be used in research related to allergic asthma, diabetes, MRSA infection, breast cancer, gastric cancer and ovarian cancer .
    Kaempferol 3-O-gentiobioside
  • HY-117358
    KW-5805

    		Biochemical Assay Reagents Inflammation/Immunology
    KW-5805 is an orally effective anti-ulcer agent that potently inhibits gastric injury induced by various necrotizing agents. KW-5805 enhances the activity of gastric mucosal glucosamine synthetase, increases the levels of gastric adherent mucus and mucosal glycoproteins, and promotes the biosynthesis, storage and secretion of gastric mucus. KW-5805 inhibits the reduction of gastric mucosal blood volume and oxygen supply caused by hemorrhagic shock. KW-5805 suppresses the development of experimental gastric and duodenal ulcers, necrotizing agent-induced gastric mucosal injury, and induced gastric acid secretion. KW-5805 can be used in ulcer-related research .
    KW-5805
  • HY-105094
    Leminoprazole

    NC 1300O3

    		 Na+/K+ ATPase Inflammation/Immunology
    Leminoprazole (NC 1300O3) is an inhibitor for acid pump, H + K +-ATPase,. Leminoprazole stimulates the secretion and synthesis of gastric mucus, attenuates gastric ulcers. Leminoprazole is orally active .
    Leminoprazole
  • HY-19170
    Z-300

    		Histamine Receptor Inflammation/Immunology
    Z-300 is a selective and orally active histamine H2-receptor antagonist. Z-300 inhibits acid secretion and promotes gastric mucus metabolism in the corpus region .
    Z-300
  • HY-165489
    AU-006

    		Endogenous Metabolite Inflammation/Immunology Endocrinology
    AU-006 is an orally active inhibitor of gastric acid secretion, with anti-ulcer effects. AU-006 does not rely on NO and mucus regulation. AU-006 significantly prevents 95% of gastric mucosal damage caused by ethanol and has broad-spectrum protective effects against chemical corrosive damage. AU-006 can be used for research on gastric ulcers .
    .
    AU-006
  • HY-B0758R
    Troxipide (Standard)

    		Calcium Channel Reference Standards Inflammation/Immunology
    Troxipide (Standard) is the analytical standard of Troxipide. This product is intended for research and analytical applications. Troxipide is an orally active defensive factor-enhancing therapeutic agent for gastritis and gastric ulcer (GU). Troxipide is a non-antisecretory gastro protective agent with antiulcer, anti-inflammatory and mucus-secreting properties .
    Troxipide (Standard)
  • HY-B0160R
    Lafutidine (Standard)

    FRG-8813 (Standard)

    		 Reference Standards Histamine Receptor Metabolic Disease Endocrinology
    Lafutidine (Standard) is the analytical standard of Lafutidine. This product is intended for research and analytical applications. Lafutidine (FRG-8813) is a histamine H2-receptor antagonist (H2RA), with proven gastric mucosal protective effects. Lafutidine can be used for the research of gastroesophageal reflux disease .
    Lafutidine (Standard)

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: